A unique technology that makes it possible to produce native membrane proteins in a concentrated form outside the cell.
Breakthrough exosome solution
Ciloa offers research organizations and biotechnology companies its patented technology. The patents is based on the discovery of an exosomal signal peptide that contains motifs likely to interact with the so-called ESCRT proteins. The technology takes also advantage of expression in proprietary XO-modified cell lines.
Merging the exosomal signal peptide with a membrane protein triggers its active sorting and secretion with exosomes. Ciloa succeeds in the challenge of actively connecting two natural cellular pathways:
- The ER/Golgi pathway that enables the synthesis, proper folding, and post-translational modifications of membrane proteins.
- A specific sorting pathway that allows the secretion, outside cells, of membrane proteins inserted in the membranes of natural nanovesicles called exosomes.
Because it uses entirely natural pathways, the ciloa technological platform makes it possible to produce membrane proteins with the true native conformations in a concentrated form outside the cell.
The core know-how of ciloa technology to successfully combine these two pathways was elaborated in an academic laboratory, and is protected by CNRS and University of Montpellier II patents.